论文部分内容阅读
目的观察重组人脑利钠肽(rh BNP)治疗硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重的临床效果。方法 20例扩张型心肌病慢性心力衰竭急性加重硝普钠治疗效果欠佳的患者为研究对象,观察重组人脑利钠肽治疗前后患者临床症状、体征及心功能改善情况,对临床效果进行评价。结果治疗后,心率(HR)、脑利钠肽(BNP)较治疗前明显降低,差异有统计学意义(P<0.001);左室射血分数(LVEF)、左室舒张末期内径(LVEDd)均较治疗前有明显改善,差异有统计学意义(P<0.001)。结论重组人脑利钠肽对于治疗硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重具有较好的临床作用且不良反应少,可在临床推广应用。
Objective To observe the clinical effect of recombinant human brain natriuretic peptide (rh BNP) on the acute worsening of chronic heart failure with dilated cardiomyopathy. Methods Twenty patients with dilated cardiomyopathy who had acute exacerbation of chronic heart failure treated with sodium nitroprusside were enrolled in this study. The clinical symptoms, signs and improvement of cardiac function were observed before and after treatment with recombinant human brain natriuretic peptide. The clinical effects were evaluated . Results After treatment, heart rate (HR) and brain natriuretic peptide (BNP) were significantly lower than those before treatment (P <0.001); left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter Compared with before treatment, there was a significant improvement, the difference was statistically significant (P <0.001). Conclusion Recombinant human brain natriuretic peptide has a good clinical effect and little adverse reaction for the treatment of acute worsening of chronic heart failure with dilated cardiomyopathy caused by poor efficacy of sodium nitroprusside. It can be widely used in clinic.